21.10 — Manufacture of basic pharmaceutical products
NACE Rev. 2.1 21.10 (Manufacture of basic pharmaceutical products) classifies within economic division 21 (Governed by Directive 2001/83/EC, EMA/National Marketing Authorization, EU GMP Annex 1, and Falsified Medicines serialization), linking EU/UN activity boundaries with US NAICS, UK SIC, and national regulatory obligations.
Eurostat • v2.1
Manufacture of basic pharmaceutical products
NAICS 325199 • SIC 21100
MCC 5122
Activity Scope, Operators & Exclusions
Who Uses This Code & Typical Business Models
- Active pharmaceutical ingredient (API) and finished drug makers
- Vaccine, biologic, serum, and diagnostic preparation labs
- Veterinary medicine and medicated surgical dressing manufacturers
This Class Includes
2- manufacture of active pharmaceutical ingredients to be used for their pharmacological properties in the manufacture of medical products (e.g. antibiotics, basic vitamins, salicylic and O-acetylsalicylic acids)
- processing of blood
Also Includes
- manufacture of chemically pure sugars
- manufacture of probiotics
- processing of glands and manufacture of extracts of glands, etc.
This Class Excludes (Cross-References)
1- manufacture of advanced cell and gene therapy pharmaceutical preparations, see 21.20
Legislation, Licensing, Incorporation & Tax Framework
Governing Statutes & Regulations
Mandatory Permits, Licenses & Authorities
- TİTCK Manufacturing Authorization, Good Manufacturing Practice (GMP) Certificate, and Drug Marketing Authorizations
- İTS serialization integration & mandatory Qualified Person (Mesul Müdür)
- Ministry of Agriculture Veterinary Drug License for 21.20 animal formulations
Incorporation Route & Chamber Registration
- EU NACE Rev. 2.1 Framework
- Governed by Directive 2001/83/EC, EMA/National Marketing Authorization, EU GMP Annex 1, and Falsified Medicines serialization.
- United States (IRS / SBA / NAICS)
- Maps to NAICS 3254. Requires FDA NDA/ANDA/BLA approval, strict 21 CFR 210/211 cGMP inspection, and DSCSA serialization.
- United Kingdom (Companies House / HMRC)
- Requires MHRA Manufacturer’s Licence (MIA), Marketing Authorisation, and Qualified Person batch release under UK SIC 21xxx.
VAT, Withholding & Statutory Incentives
- Licensed pharmaceuticals carry 10% reduced VAT in Turkey.
- Classified as High-Technology Manufacturing: qualifies for KOSGEB Business Dev grants, Law 5746 R&D Center deductions, and Priority/Strategic Investment Incentives.
Cross-Border Regulatory Frameworks (EU / US / UK)
Chamber of Industry / Commerce + Industrial Registry (Capital Company required) — JSC/LLC structure mandatory for GMP pharmaceutical manufacturing.
Governed by Directive 2001/83/EC, EMA/National Marketing Authorization, EU GMP Annex 1, and Falsified Medicines serialization.
Classification Boundaries & Audit Risks
- Dietary supplements and vitamins belong in Div. 10 (10.89) under Food Law, not Div. 21 drugs.
- Non-medicated medical devices and surgical instruments sit in Div. 32 (32.50).
Turkish 6-Digit NACE Subclasses & OHS Hazard Classes
| 6-Digit Code | Official Turkish Activity Definition | OHS Hazard | Office / Location | Guide |
|---|---|---|---|---|
| Temel eczacılık ürünlerinin hammaddelerinin imalatı (antibiyotik, vitamin, salisilik asit gibi ilaçların imalatında farmakolojik özelliklerinden yararlanmak üzere tıbbi olarak etken maddeler ile kan ürünlerinin, salgı bezi ve ekstrelerin, hormonların vb. imalatı) (Kanın işlenmesi dahil) | Very Hazardous (Çok Tehlikeli) | Fiziki İşyeri ve Belediye Ruhsatı Şart | Inspect → |
Global Classification Passport
Verified structural and concordance mappings across EU, US, UK, UN, and national registries.
Payment Processing & ISO 18245 MCC Profile
Visa / Mastercard ISO 18245Strictly underwritten: non-OTC pharmaceuticals require pharmacy licensing and Card Brand high-risk registration.
Critical Distinctions & Sibling Codes
21.20 — Manufacture of pharmaceutical preparations
Official NACE Rev. 2.1 code 21.20: manufacture of medicaments: antisera and other blood fractions ; vaccines ; diverse medicaments, including homeopathic preparations
Classification Hierarchy & Data Export
- C Manufacturing
- 21 Manufacture of basic pharmaceutical products and pharmaceutical preparations
- 21.1 Manufacture of basic pharmaceutical products
- 21.10 Manufacture of basic pharmaceutical products
Frequently Asked Questions
What business activities and models fall under NACE Rev. 2.1 21.10?
21.10 (Manufacture of basic pharmaceutical products): manufacture of active pharmaceutical ingredients to be used for their pharmacological properties in the manufacture of medical products (e.g. antibiotics, basic vitamins, salicylic and O-acetylsalicylic acids); processing of blood. Typical operators: Active pharmaceutical ingredient (API) and finished drug makers; Vaccine, biologic, serum, and diagnostic preparation labs.
What regulatory licensing and tax rules apply to 21.10 across EU, US, UK, or Turkey?
EU: Governed by Directive 2001/83/EC, EMA/National Marketing Authorization, EU GMP Annex 1, and Falsified Medicines serialization. US: Maps to NAICS 3254. Requires FDA NDA/ANDA/BLA approval, strict 21 CFR 210/211 cGMP inspection, and DSCSA serialization. UK: Requires MHRA Manufacturer’s Licence (MIA), Marketing Authorisation, and Qualified Person batch release under UK SIC 21xxx.
What are the international classification equivalents and MCC code for 21.10?
Verified concordance for 21.10: US NAICS 2022: 325199 (All Other Basic Organic Chemical Manufacturing), 325411 (Medicinal and Botanical Manufacturing), 325412 (Pharmaceutical Preparation Manufacturing) • UK SIC 2007: 21100 (Manufacture of basic pharmaceutical products) • Payment MCC 5122 (Drugs, Drug Proprietaries and Druggists Sundries).
What was 21.10 under legacy NACE Rev. 2?
Under official Eurostat concordance, NACE Rev. 2.1 21.10 corresponds to NACE Rev. 2 21.10 (Manufacture of basic pharmaceutical products).
Which activities are excluded from NACE Rev. 2.1 21.10?
Official explanatory notes exclude: manufacture of advanced cell and gene therapy pharmaceutical preparations, see 21.20.